{"public_id":"co_49f489ced3248a8c24026ff877064fc4","status":"active","merged_into_public_id":null,"resolved_public_id":"co_49f489ced3248a8c24026ff877064fc4","name":"severe COVID-19 patients","description":"The cohort of ten hospitalized patients with severe Coronavirus Disease 2019 who were enrolled and treated in this trial.","aliases":[],"types":["population"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":235887814,"title":"Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients","citation_count":12,"url":"https://sah.borca.ai/papers/235887814"}],"claims":[{"public_id":"cl_1093e947dd59b05524b2d59e3f901e75","text":"Nine of ten severe COVID-19 patients treated with aaPRP recovered and were transferred from the ICU to the ward, while one patient died in the ICU due to heart failure.","corpus_id":235887814,"url":"https://sah.borca.ai/claims/cl_1093e947dd59b05524b2d59e3f901e75"},{"public_id":"cl_b63a7cedbc46be3c1639bf1f663b44af","text":"Ten severe COVID-19 patients admitted to the ICU received autologous activated platelet-rich plasma (aaPRP) administered three times in a phase I/II trial.","corpus_id":235887814,"url":"https://sah.borca.ai/claims/cl_b63a7cedbc46be3c1639bf1f663b44af"},{"public_id":"cl_bc61d98ac00effa2d9bf27d2a17808b6","text":"aaPRP administration in severe COVID-19 patients was safe and not associated with serious adverse events, supporting its potential as an adjunctive therapy.","corpus_id":235887814,"url":"https://sah.borca.ai/claims/cl_bc61d98ac00effa2d9bf27d2a17808b6"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_49f489ced3248a8c24026ff877064fc4","url":"https://sah.borca.ai/concepts/co_49f489ced3248a8c24026ff877064fc4"}